---
title: "CKLIFE SCIENCES Li Zeju: Buying stocks is purely for collecting dividends, there is no reason to invest in the biotechnology industry"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/241344478.md"
description: "Li Zeju, Chairman of CKLIFE SCIENCES, stated at the shareholders' meeting that the biotechnology industry has high returns and high risks, and if the only goal is to earn interest, one should not invest in this industry. He mentioned that the company will evaluate strategic opportunities for divesting the biopharmaceutical sector to enhance shareholder value. Regarding plans to raise funds, Li Zeju indicated that there is currently no relevant news, but the company will allocate capital rigorously. The performance of health products and agriculture-related businesses is good, providing important resources for scientific research and development"
datetime: "2025-05-22T03:28:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/241344478.md)
  - [en](https://longbridge.com/en/news/241344478.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/241344478.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/241344478.md) | [繁體中文](https://longbridge.com/zh-HK/news/241344478.md)


# CKLIFE SCIENCES Li Zeju: Buying stocks is purely for collecting dividends, there is no reason to invest in the biotechnology industry

Li Zeju, Chairman of CKLIFE SCIENCES (00775.HK), was asked about his views on the company's prospects after the shareholders' meeting. He pointed out that biotechnology research is a high-return, high-risk industry. If successful, the value of a single product could surpass many listed infrastructure and even real estate companies. However, if unsuccessful, there is nothing to say. Therefore, he believes that if one is buying stocks purely for dividends, there is no reason to invest in the biotechnology sector. However, if there is a comprehensive investment portfolio, allocating a portion of funds to such high-risk, high-reward investments is correct.

When asked whether he is considering spinning off the biopharmaceutical division and listing it under Chapter 18A of Hong Kong law, Li Zeju stated that the company will continue to evaluate strategic opportunities to enhance shareholder value and optimize its business structure. As for whether there will be a share placement, issuance of convertible bonds, or sale of non-core assets to raise funds to support research, Li Zeju indicated that the company will allocate capital rigorously, but there are currently no announcements regarding fundraising plans. He also mentioned that the health products business and agriculture-related business are important segments for the company, with operational performance remaining ideal and generating robust cash flow, providing essential resources for research and development

### Related Stocks

- [CKLIFE SCIENCES (00775.HK)](https://longbridge.com/en/quote/00775.HK.md)

## Related News & Research

- [CK Life Sciences Forms New Unit to Advance Cancer Vaccine Research](https://longbridge.com/en/news/278525401.md)
- [Tommy DeCarlo, lead singer of Boston, dies at 60](https://longbridge.com/en/news/278537939.md)
- [Japan PM Takaichi cancels official duties over suspected cold symptoms, Jiji reports](https://longbridge.com/en/news/278859414.md)
- [Fosun Pharmaceutical Unit Gets Clinical Trial Approval for Cancer Drug](https://longbridge.com/en/news/278501201.md)
- [HUTCHMED to Withdraw Cancer Drug TAZVERIK in Greater China After Ipsen Safety Move](https://longbridge.com/en/news/278365432.md)